5-HT3 Receptor Antagonists include-
Alosetron, Dolasetron, Ondansetron, Palonosetron, Granisetron, Hydrolastron

Refer - 5-HT3 Receptor Antagonists

5-HT3 Receptor Antagonists include-
Alosetron, Dolasetron, Ondansetron, Palonosetron, Granisetron, Hydrolastron

Refer - 5-HT3 Receptor Antagonists

Prevention of nausea and vomiting associated with chemotherapy

Adverse reactions-

DOLASETRON- ( Oral and Injections)

Cardiovascular -  Hypotension ( infrequent)  atrial fibrillation/flutter,
                               bundle braepitaxich block ( left and right )  chest pain,  edema,
                               extrasystole, nodal arrhythmias,  orthostatic myocardial infarction,
                               palpitations, peripheral edema, peripheral ischemia,
                               Bradycardia, severe hypotension and syncope have been reported
                               immediately or closely following IV administration.

CNS-                   agitation, depersonalization, flushing, parathesia, sleep disorder,
                            tremor, vertigo ( infrequent ) abnormal dreaming, anxiety, ataxia,
                            confusion ,twitching ( rare )

Dermatologic -  increase sweating, rash, ( infrequent )

GI-                       abnormal pain, anoexia, constipation, dyspepsia ( infrequent )
                            pancreatitis ( rare )

GU-                    acute renal failure, dysuria, ployuria ( rare ) 

Hematologic -    anemia,  epitaxis,  hematuria, partial thromboplastin time prolonged,
                             purpra/hematoma, thrombocytopenia ( rare )

Hepatic -            transcient increase in ALT  and or AST  values ( < 1% ),
                            hyperbilirubinemia, increased gamma-glutamyltransferace ( rare )

Metabolic -         alkaline phosphatase inceased ( rare )

Musculoskeletal -   arthalgia, myalgia ( rare )

Ophthalmic -         abnormal vision ( infrequent )  photophobia ( rare )

Respiratoy -       bronchospasm, dyspnea ( rare )

Special senses -  taste pervertion ( infrequent ) tinnitus ( rare )

Miscellaneous-   anaphylactic reaction, facial edema, local pain or burning on
                              IV administration , urticaria ( rare )

5-HT3 Receptor Antagonists include-
Alosetron, Dolasetron, Ondansetron, Palonosetron, Granisetron, Hydrolastron

Refer - 5-HT3 Receptor Antagonists

Indication-
Prevention of nausea and vomiting associated with chemotherapy

Dosage- oral
Usual dosage - 100mg given within 1 hour before chemotherapy
Maximum dose 100mg

Children-  2 to 6 years-
Usual dosage- 1.2mg/kg within 2 hours before surgery
Maximum dose - 100mg

Dosage - Injection
Usual dosage-  1.8mg/kg IV given as a single dose approximately 30 minutes before
chemotherapy

Alternative dosage-  Alternatively for most patients, a fixed dose of 100mg  can be
administered IV for 30 seconds

Children-
2 to 16 years-
Usual dosage- 1.8mg/kg IV given as a single dose approimately 30 minutes before
chemotherapy

5-HT3 Receptor Antagonists include-
Alosetron, Dolasetron, Ondansetron, Palonosetron, Granisetron, Hydrolastron

Refer - 5-HT3 Receptor Antagonists

5-HT3 Receptor Antagonists include-
Alosetron, Dolasetron, Ondansetron, Palonosetron, Granisetron, Hydrolastron

Refer - 5-HT3 Receptor Antagonists

5-HT3 Receptor Antagonists include-
Alosetron, Dolasetron, Ondansetron, Palonosetron, Granisetron, Hydrolastron

Refer - 5-HT3 Receptor Antagonists